Brian Schulte, MD
Assistant Professor
Medicine
School of Medicine

In research, Dr. Schulte studies novel medications, alone and in combination, to treat sarcoma. After earning a bachelor's degree in engineering at Duke University, Dr. Schulte earned his medical degree at the Medical College of Wisconsin and completed a residency in internal medicine at the University of Colorado Anschutz Medical Campus. He completed a fellowship in hematology-oncology at Northwestern University Feinberg School of Medicine, where he served as chief fellow.

• Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma.
  Frontiers in oncology 2023 Fuchs JR, Schulte BC, Fuchs JW, Agulnik M
• B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
  Molecular cancer therapeutics 2022 Zhang S, Black RG, Kohli K, Hayes BJ, Miller C, Koehne A, Schroeder BA, Abrams K, Schulte BC, Alexiev BA, Heimberger AB, Zhang A, Jing W, Ng JCK, Shinglot H, Seguin B, Salter AI, Riddell SR, Jensen MC…
• CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
  Journal for immunotherapy of cancer 2021 Schroeder BA, LaFranzo NA, LaFleur BJ, Gittelman RM, Vignali M, Zhang S, Flanagan KC, Rytlewski J, Riolobos L, Schulte BC, Kim TS, Chen E, Smythe KS, Wagner MJ, Mantilla JG, Campbell JS, Pierce RH, …
• An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma.
  European journal of cancer (Oxford, England : 1990) 2021 Agulnik M, Schulte B, Robinson S, Hirbe AC, Kozak K, Chawla SP, Attia S, Rademaker A, Zhang H, Abbinanti S, Cehic R, Monga V, Milhem M, Okuno S, Van Tine BA
• Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors.
  BMJ case reports 2021 Principe DR, Schulte BC, Kamath SD, Munshi HG
• Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
  British journal of cancer 2021 Schulte B, Mohindra N, Milhem M, Attia S, Robinson S, Monga V, Hirbe AC, Oppelt P, Charlson J, Helenowski I, Abbinanti S, Cehic R, Okuno S, Van Tine BA, Agulnik M
• Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report.
  The oncologist 2021 Lambden JP, Kelsten MF, Schulte BC, Abbinanti S, Hayes JP, Villaflor V, Agulnik M
• Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2020 Schulte B, Morgans AK, Shore ND, Pezaro C
• Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system.
  Drug design, development and therapy 2018 Zhang W, Jordan KR, Schulte B, Purev E
• Azelaic Acid: Evidence-based Update on Mechanism of Action and Clinical Application.
  Journal of drugs in dermatology : JDD 2015 Schulte BC, Wu W, Rosen T
• Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.
  The Journal of investigative dermatology 2014 Wu X, Schulte BC, Zhou Y, Haribhai D, Mackinnon AC, Plaza JA, Williams CB, Hwang ST